RLMD NASDAQ
Relmada Therapeutics, Inc.
1W: -6.0%
1M: -20.7%
3M: -43.1%
YTD: -17.6%
1Y: +66.7%
3Y: +357.1%
5Y: -38.1%
$3.60
-0.06 (-1.64%)
Weekly Expected Move ±9.0%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-07-20
Earliest Filing
2025-03-26
Latest Filing
investor: 5
licensee: 1
target: 1
partner: 1
Counterparties (Filed by RLMD)
8 relationshipsCompanies named in RLMD's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Trigone Pharma, Ltd. | — | licensee | Relmada entered into an exclusive license agreement to obtain rights to Trigone's fixed dose formulation of gemcitabine | 2025-03-26 | View |
| Asarina Pharma AB | — | target | Seller of Sepranolone asset rights to Relmada Therapeutics, Inc. | 2025-02-06 | View |
| Venrock Healthcare Capital Partners EG, L.P. | — | investor | Received pre-funded warrants in exchange for common stock | 2022-09-22 | View |
| Venrock Healthcare Capital Partners II, L.P. | — | investor | Received pre-funded warrants in exchange for common stock | 2022-09-22 | View |
| VHCP Co-Investment Holdings II, LLC | — | investor | Received pre-funded warrants in exchange for common stock | 2022-09-22 | View |
| Venrock Healthcare Capital Partners III, L.P. | — | investor | Received pre-funded warrants in exchange for common stock | 2022-09-22 | View |
| VHCP Co-Investment Holdings III, LLC | — | investor | Received pre-funded warrants in exchange for common stock | 2022-09-22 | View |
| Arbormentis LLC | — | partner | Relmada acquired development and commercial rights to a psilocybin program and will collaborate on new therapies. | 2021-07-20 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-08 | Other Events | View | |
| 2026-08-06 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-07-28 | Regulation FD; Exhibits | View | |
| 2026-05-28 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-05-12 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-03-09 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-12-15 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-05 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-11-04 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-17 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-09-16 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-10 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-09-02 | Regulation FD Disclosure | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-23 | Notice of Delisting or Transfer | View | |
| 2025-07-10 | Termination of Material Definitive Agreement | View | |
| 2025-06-18 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-27 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-12 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR